1. Home
  2. CBAY


CymaBay Therapeutics Inc.

Logo CymaBay Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations



CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Founded: N/A Country:
United States
United States
Employees: N/A City: NEWARK
Market Cap: 3.7B IPO Year: N/A
Target Price: $27.85 AVG Volume (30 days): 3.9M
Analyst Decision: Hold Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.99 EPS Growth: N/A
52 Week Low/High: $7.26 - $32.50 Next Earning Date: 05-13-2024
Revenue: $31,073,000 Revenue Growth: N/A
Revenue Growth (this year): -61.51% Revenue Growth (next year): 877.59%

Share on Social Networks: